BACKGROUND: Pancreatic cancer is a multifactorial disease with metastasis-prone and therapy-resistant nature. The authors hypothesized that genetic variants of glutathione S-transferase (GST) affect detoxification of carcinogens and anticancer agents in the human pancreas and, thus, the risk and survival of pancreatic cancer. METHODS: Genotypes of GSTM1, GSTT1, and GSTP1 were determined in 352 patients with pancreatic ductal adenocarcinoma and in a control group of 315 healthy, non-Hispanic whites (frequency-matched by age and sex). Survival analysis was performed in a subset of 290 patients. Epidemiological and clinical information was obtained. A multiple unconditional logistic regression model, a Cox proportional hazards model, and log-rank tests were used for statistical analysis. RESULTS: No significant main effects of any of 3 GST genes on the risk of pancreatic cancer were observed. Subgroup analysis showed that older individuals (aged >or=62 years) who carried the GSTP1*C ((105)Val-(114)Val) containing genotype tended to have a reduced risk compared with younger individuals who carried the non-*C genotype (for sex and pack-years of smoking, the adjusted odd ratio was 0.54; 95% confidence interval [95% CI], 0.29-1.02). In a survival analysis of 138 patients who received 5-flurorouracil, patients who carried the GSTP1*C containing genotype had a significantly longer survival than patients who carried the non-*C genotype (multivariate hazard ratio, 0.45; 95% CI, 0.22-0.94). CONCLUSIONS: The GSTP1*C variant conferred a possible protective effect against pancreatic cancer in older individuals and a significant survival advantage in patients who received 5-florouracil. The current findings must be confirmed before further inferences can be made.
BACKGROUND:Pancreatic cancer is a multifactorial disease with metastasis-prone and therapy-resistant nature. The authors hypothesized that genetic variants of glutathione S-transferase (GST) affect detoxification of carcinogens and anticancer agents in the humanpancreas and, thus, the risk and survival of pancreatic cancer. METHODS: Genotypes of GSTM1, GSTT1, and GSTP1 were determined in 352 patients with pancreatic ductal adenocarcinoma and in a control group of 315 healthy, non-Hispanic whites (frequency-matched by age and sex). Survival analysis was performed in a subset of 290 patients. Epidemiological and clinical information was obtained. A multiple unconditional logistic regression model, a Cox proportional hazards model, and log-rank tests were used for statistical analysis. RESULTS: No significant main effects of any of 3 GST genes on the risk of pancreatic cancer were observed. Subgroup analysis showed that older individuals (aged >or=62 years) who carried the GSTP1*C ((105)Val-(114)Val) containing genotype tended to have a reduced risk compared with younger individuals who carried the non-*C genotype (for sex and pack-years of smoking, the adjusted odd ratio was 0.54; 95% confidence interval [95% CI], 0.29-1.02). In a survival analysis of 138 patients who received 5-flurorouracil, patients who carried the GSTP1*C containing genotype had a significantly longer survival than patients who carried the non-*C genotype (multivariate hazard ratio, 0.45; 95% CI, 0.22-0.94). CONCLUSIONS: The GSTP1*C variant conferred a possible protective effect against pancreatic cancer in older individuals and a significant survival advantage in patients who received 5-florouracil. The current findings must be confirmed before further inferences can be made.
Authors: Aaron L Trachte; Sara E Suthers; Megan R Lerner; Jay S Hanas; Eldon R Jupe; Anna E Sienko; Adekunle M Adesina; Stan A Lightfoot; Daniel J Brackett; Russell G Postier Journal: Am J Surg Date: 2002-12 Impact factor: 2.565
Authors: Yunfei Wang; Margaret R Spitz; Matthew B Schabath; Francis Ali-Osman; Hilario Mata; Xifeng Wu Journal: Lung Cancer Date: 2003-04 Impact factor: 5.705
Authors: K D Tew; A Monks; L Barone; D Rosser; G Akerman; J A Montali; J B Wheatley; D E Schmidt Journal: Mol Pharmacol Date: 1996-07 Impact factor: 4.436
Authors: M Fatih Okcu; Mano Selvan; Li-E Wang; Linda Stout; Rodrigo Erana; Gladstone Airewele; Phyllis Adatto; Kenneth Hess; Francis Ali-Osman; Morris Groves; Alfred W K Yung; Victor A Levin; Qingyi Wei; Melissa Bondy Journal: Clin Cancer Res Date: 2004-04-15 Impact factor: 12.531
Authors: Mia Hashibe; Paul Brennan; Richard C Strange; Rajani Bhisey; Ingolf Cascorbi; Philip Lazarus; Michael B Oude Ophuis; Simone Benhamou; William D Foulkes; Takahiko Katoh; Christiane Coutelle; Marjorie Romkes; Laura Gaspari; Emanuela Taioli; Paolo Boffetta Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-12 Impact factor: 4.254
Authors: Rick J Jansen; Dennis P Robinson; Rachael Z Stolzenberg-Solomon; William R Bamlet; XiangLin Tan; Julie M Cunningham; Ying Li; David N Rider; Ann L Oberg; Kari G Rabe; Kristin E Anderson; Rashmi Sinha; Gloria M Petersen Journal: Pancreas Date: 2013-10 Impact factor: 3.327
Authors: Kenneth D Tew; Yefim Manevich; Christina Grek; Ying Xiong; Joachim Uys; Danyelle M Townsend Journal: Free Radic Biol Med Date: 2011-04-22 Impact factor: 7.376
Authors: Georgios Voidonikolas; Stephanie S Kreml; Changyi Chen; William E Fisher; F Charles Brunicardi; Richard A Gibbs; Marie-Claude Gingras Journal: World J Surg Date: 2009-04 Impact factor: 3.352